Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene OK'd to Start US Trial of PD-1 Cancer Drug

publication date: Jan 13, 2016
BeiGene, a Beijing novel cancer drug company, will start a US Phase Ia/b clinical trial of BGB-A317, the company's humanized mAb that targets the immune checkpoint receptor PD-1. BeiGene expects to develop the molecule as a monotherapy and in combination with other cancer drugs to treat solid-organ and blood-borne cancers. The US tests will be part of a global trial; Australian tests are already underway, with 51 patients dosed by the end of November 2015. The trials are enrolling patients with relapsed or refractory solid tumors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital